CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
10.3802/jgo.2013.24.2.141
- Author:
Naoto FURUKAWA
1
;
Yoshikazu SASAKI
;
Aiko SHIGEMITSU
;
Juria AKASAKA
;
Seiji KANAYAMA
;
Ryuji KAWAGUCHI
;
Hiroshi KOBAYASHI
Author Information
1. Department of Obstetrics and Gynecology, Nara Medical University, Nara, Japan. furunao0813@gmail.com
- Publication Type:Original Article
- Keywords:
CA125;
Interval debulking;
Neoadjuvant chemotherapy;
Ovarian cancer
- MeSH:
Gynecology;
Humans;
Logistic Models;
Multivariate Analysis;
Neoplasms, Glandular and Epithelial;
Obstetrics;
Odds Ratio;
Ovarian Neoplasms;
Retrospective Studies;
ROC Curve
- From:Journal of Gynecologic Oncology
2013;24(2):141-145
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: In the present study, we evaluated changes in CA-125 cut-off values predictive of complete interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) using receiver operating characteristic (ROC) analysis. METHODS: This retrospective single-institution study included patients with International Federation of Gynecology and Obstetrics (FIGO) stage III epithelial ovarian cancer and a pre-NAC serum CA-125 level of greater than 40 U/mL who were treated with neoadjuvant platinum-based chemotherapy followed by IDS between 1994 and 2009. Logistic regression analysis was used to evaluate univariate and independent multivariate associations with the effect of clinical, pathological, and CA-125 parameters on complete IDS, and ROC analysis was used to determine potential cut-off values of CA-125 for prediction of the possibility of complete IDS. RESULTS: Seventy-five patients were identified. Complete IDS was achieved in 46 (61.3%) patients and non-complete IDS was observed 29 (38.7%). Median pre-NAC CA-125 level was 639 U/mL (range, 57 to 6,539 U/mL) in the complete IDS group and 1,427 U/mL (range, 45 to 10,989 U/mL) in the non-complete IDS group. Median pre-IDS CA-125 level was 15 U/mL (range, 2 to 60 U/mL) in the complete IDS group and 53 U/mL (range, 5 to 980 U/mL) in the non-complete IDS group (p<0.001). Multivariate analyses performed with complete IDS as the endpoint revealed only pre-IDS CA-125 as an independent predictor. The odds ratio of non-complete IDS was 10.861 when the pre-IDS CA-125 level was greater than 20 U/mL. CONCLUSION: The present data suggest that in the setting of IDS after platinum-based NAC for advanced ovarian cancer, a pre-IDS CA-125 level less than 20 U/mL is an independent predictor of complete IDS.
